Results: Although no individual single-nucleotide polymorphisms (SNPs) achieved genome-wide significance, the GWAS signals were enriched for SNPs strongly associated with variations in brain gene expression levels (expression quantitative loci, or eQTLs), suggesting the presence of true functional variants that contribute to risk of these disorders. Polygenic score analyses identified a significant polygenic component for OCD (p=2310 24 ), predicting 3.2% of the phenotypic variance in an independent data set. In contrast, Tourette's syndrome had a smaller, nonsignificant polygenic component, predicting only 0.6% of the phenotypic variance (p=0.06). No significant polygenic signal was detected across the two disorders, although the sample is likely underpowered to detect a modest shared signal. Furthermore, the OCD polygenic signal was significantly attenuated when cases with both OCD and co-occurring Tourette's syndrome/chronic tics were included in the analysis (p=0.01).
Conclusions:
Previous work has shown that Tourette's syndrome and OCD have some degree of shared genetic variation. However, the data from this study suggest that there are also distinct components to the genetic architectures of these two disorders. Furthermore, OCD with co-occurring Tourette's syndrome/chronic tics may have different underlying genetic susceptibility compared with OCD alone. (4) (5) (6) . Both disorders are characterized by the presence of repetitive, ritualized, or stereotyped behaviors (tics and compulsions), often preceded by cognitive or sensory phenomena (premonitory urges and obsessions), and clinical differentiation of compulsions versus complex tics can be challenging (7) . Genetic epidemiological studies suggest up to 90% shared genetic variance between Tourette's syndrome/chronic tics and OCD (8) (9) (10) , and abnormalities in cortico-striatal-thalamocortical circuitry have been identified in both conditions (1) . To date, most of the work aimed at elucidating the genetic causes of Tourette's syndrome and OCD has focused on candidate gene studies and linkage analyses; a few studies examining chromosome abnormalities and copy number variants have also been reported (11) (12) (13) (14) . Recently, our group performed genome-wide association studies (GWAS) of Tourette's syndrome and OCD, and for each disorder identified a number of genes and genomic regions of interest, most with modest significance levels. Here we report GWAS results for a combined sample of individuals with Tourette's syndrome, OCD, or Tourette's syndrome plus OCD, along with analyses aimed at elucidating the genetic architectures and genetic relationships between the two disorders. Combining these heterogeneous but related phenotypes in joint analyses could have one of two potential effects: 1) enhancement of the genetic signal as a consequence of increased power by adding samples from genetically related phenotypes; or 2) reduction of the genetic signal as a consequence of increased genetic heterogeneity, outweighing the potential benefits of increased sample size. Either way, given previous evidence supporting shared genetic factors and the lack of definitive susceptibility genes for either disorder, joint analyses of Tourette's syndrome and OCD cases represent an important step toward understanding the underlying causes of these common neuropsychiatric disorders.
METHOD

Cases
Individuals with Tourette's syndrome or OCD were recruited as part of collaborative efforts to conduct the first GWAS for these disorders (for details, see references 15, 16) . Although data were collected independently for Tourette's syndrome and OCD, all genotyping and data cleaning were done together, facilitating joint analyses. Participants who were age 18 or older provided written, voluntary informed consent; those under age 18 provided assent, and written parental consent for their participation was obtained. The study was approved by the ethics committees of all participating sites and was in accordance with the Declaration of Helsinki. For the cross-disorder analyses, any participant with either Tourette's syndrome or OCD was considered affected. For details on the inclusion and exclusion criteria and assessment protocols, see the Supplementary Methods section in the data supplement that accompanies the online edition of this article.
Tourette's syndrome. The Tourette's syndrome sample consisted of 1,286 individuals recruited from 20 sites in the United States, Canada, the United Kingdom, the Netherlands, and Israel, and included individuals of general European (EU) ancestry as well as two EU-derived population isolates of Ashkenazi Jewish (AJ) and French Canadian (FC) descent. Co-occurring OCD symptoms were assessed in 77% of participants; 46% of those evaluated had co-occurring OCD (N=452). OCD status was unknown for 300 individuals with Tourette's syndrome.
[SA] descent) were included in the present study (16) . Cooccurring Tourette's syndrome or chronic tics was assessed in 77% of OCD probands; of these, 12% had comorbid Tourette's syndrome or chronic tics (N=159). Tourette's syndrome/chronic tics status was unknown for 405 OCDaffected individuals.
Controls
The EU control sample consisted of 4,975 European Caucasian controls primarily derived from cohorts of previously genotyped, unselected population controls (see Supplementary Methods in the online data supplement). Ancestrymatched controls for the FC (N=196) and SA (N=158) samples were collected in parallel with their respective cases (15, 16) . Ancestry-matched controls for individuals with AJ ancestry were identified from the EU control sample based on self-reported ancestry and principal-components analysis (N=338).
Genotyping and Quality Control
Genotyping and quality control procedures have been described previously (15, 16 ; see also Supplementary Methods in the online data supplement). Briefly, case subjects and trios with Tourette's syndrome or OCD and controls were randomized across plates and genotyped on the Illumina HumanHap610 SNP array (Illumina, San Diego) at the Broad Institute of Harvard-MIT (Cambridge, Mass.) or on the Illumina HumanHap370 at the Yale Center for Genome Analysis (New Haven, Conn.) (see Figure S1 in the online data supplement). Eighty-eight samples were genotyped on both platforms to allow for cross-platform concordance checks. Quality control analyses were performed using PLINK, version 1.07 (17) and EIGENSTRAT (18) . Multidimensional scaling analysis was used to exclude case-control samples of nonEuropean descent. Remaining EU and European-derived isolate samples were separated into four strata (EU, AJ, FC, and SA) based initially on self-reported ancestry and then on observed genetic ancestry (15, 16) . Imputation was performed with 1000 Genomes Project data (June 2011 Data Release) (19) as the reference panel, using IMPUTE version 2.1.2 (20) (see Supplementary Methods).
Genome-Wide Association Analyses
Individual ancestry-stratified case-control genome-wide association analyses (EU, AJ, FC, and SA) and one case/pseudocontrol analysis using the OCD trios were performed in PLINK using logistic regression under an additive model with significant subpopulation-specific multidimensional scaling axes included as covariates to control for residual population stratification (see Figure S2 in the online data supplement). These population-specific analyses were then combined in a fixed-effects model meta-analysis using case-weighting in METAL (21 
Polygenic Score Analysis
Polygenic score analyses were conducted in PLINK using genotyped SNPs to test the hypothesis that multiple genes of small effect jointly contribute to Tourette's syndrome and OCD susceptibility and to explore the genetic relationships between these disorders (25) . Samples were divided into nonoverlapping discovery and target samples (see Supplementary Methods in the online data supplement). For the primary OCD polygenic analysis, cases were restricted to subjects without known co-occurring Tourette's syndrome/ chronic tics. SNPs with GWAS p values passing predetermined significance thresholds (p,0.01, 0.1, 0.2, 0.3, 0.4, and 0.5) in the discovery sample were extracted along with their risk alleles and odds ratios, and then linkage disequilibrium (LD) pruned (r 2 ,0.5). For each significance threshold, a quantitative aggregate risk score was calculated for each individual in the target sample, defined as the sum of the number of risk alleles present at each locus weighted by the log of the odds ratio for that locus estimated from the discovery sample. The relationship between aggregate risk score and case-control status in the target sample was examined at each significance threshold using logistic regression. The percentage of phenotypic variance explained by the aggregate risk score (Nagelkerke's pseudo-R 2 ) was estimated. Two separate statistical approaches were used to determine the significance of the observed differences in polygenic risk score prediction between discovery samples. First, permutation testing was conducted to derive an empirical significance of the magnitude of change in R 2 between polygenic risk scores derived from the discovery sample of Tourette's syndrome/chronic tics without OCD compared with those derived from the "all OCD" sample (OCD with or without Tourette's syndrome/chronic tics). Second, risk alleles from each discovery sample were used to calculate the difference in polygenic risk scores between the transmitted (case) alleles and the untransmitted (pseudo-control) alleles in the OCD trio target sample. The degree of risk score elevation (risk score transmitted 2 risk score untransmitted ) was then standardized ([risk score transmitted 2 risk score untransmitted ]/risk score untransmitted ) and compared between different discovery samples using two-sided paired t tests. For further details of both approaches, see Supplementary Methods in the online data supplement.
RESULTS
Combined Tourette's Syndrome-OCD GWAS
The final combined Tourette's syndrome-OCD data set consisted of 2,723 cases (1,310 with OCD, 834 with Tourette's syndrome, 579 with OCD and Tourette's syndrome/chronic tics), 5,667 controls, and 290 OCD trios. A total of 7,659,573 SNPs (439,840 genotyped and 7,219,733 imputed) were included in the meta-analysis. The genomic control l showed no evidence of residual population stratification or systematic technical artifacts (l GC =1.030; see Figure S3 in the online data supplement). Figure 1 ; see also Table S1 in the data supplement).
Enrichment Analyses
For Tourette's syndrome, OCD, and the combined sample, we examined the subset of disease association p values for SNPs meeting stringent criteria for eQTLs (p eQTL , 10 26 ) derived from cerebellum, parietal cortex, and frontal cortex, as well as cerebellar mQTLs (p mQTL , 10 26 ) (Figure 2 ). Using the field standard false-discovery-rate threshold of ,0.25, we identified 38 cerebellar eQTLs from five LDindependent loci for Tourette's syndrome, 161 cerebellar mQTLs (19 LD-independent loci) for OCD, and 53 parietal cortex eQTLs (four LD-independent loci) for the combined GWAS (Table 2) . Polygenic Risk Score Analysis Polygenic score analyses were conducted to test two related hypotheses: 1) that both Tourette's syndrome and OCD individually harbor multiple, small-effect, common risk alleles across the genome; and 2) that Tourette's syndrome and OCD may have shared common risk alleles (cross-disorder analyses). In the individual disorder analyses, risk scores derived from the OCD without known co-occurring Tourette's syndrome/chronic tics discovery sample strongly predicted case-control status in the OCD target sample (p=2.1310
24
), explaining 3.2% of the phenotypic variance ( Figure 3 ; see also Table S3 in the online data supplement). In contrast, risk scores derived from the Tourette's syndrome discovery sample demonstrated only weak prediction in the Tourette's syndrome target sample (p=0.06; R 2 =0.6%
of variance explained). Risk scores derived from the combined Tourette's syndrome-OCD discovery sample also predicted case-control status in the OCD target sample (p=0.0075, R 2 =1.7% of variance explained), although less robustly than those derived from the OCD discovery sample alone (p=0.01; see Figure 3 , inset). Risk scores derived from the Tourette's syndrome-OCD combined sample could not discriminate between cases and controls in the Tourette's syndrome target sample (p=0.4; see Figure 3 ; see also Table S3 in the data supplement).
In cross-disorder analyses, risk scores derived from the Tourette's syndrome discovery sample did not predict case-control status in the OCD target sample (p=0.66), nor did OCD-associated risk scores predict into the Tourette's syndrome target sample (p=0.37) (see Figure 3 and Table S3 ).
To explore the influence of phenotype comorbidity on polygenic risk score prediction, an additional all-OCD discovery sample was created that included the primary OCD discovery sample plus 345 additional case subjects with OCD plus co-occurring Tourette's syndrome/chronic tics. As expected, the polygenic score using risk alleles derived from this discovery sample predicted case-control status in the OCD target sample (p=2.3310 23 ) (Figure 3) . However, the proportion of variance explained by the all-OCD risk score was significantly attenuated compared with the risk score derived from the primary OCD without co-occurring Tourette's syndrome/chronic tics discovery sample, despite the 30% increase in sample size (OCD without co-occurring Tourette's syndrome/chronic tics, N=1,154, R 2 =3.2% of variance explained; all-OCD sample, N=1,499, R 2 =2.1% of variance explained; permutation p=0.01; see Figure 3 ; see also Figure S9 in the data supplement).
In addition, the magnitude of elevation in the polygenic risk scores (risk score elevation) between transmitted and untransmitted risk alleles in the OCD trios was calculated using risk alleles from the different OCD discovery samples and compared (see Figure 3 , inset). The risk score elevation in the OCD trios was highest when the primary OCD without co-occurring Tourette's syndrome/chronic tics discovery sample was used to derive the risk score compared to either the all-OCD sample or the combined Tourette's syndrome-OCD sample (paired t test, p=0.022 and p=0.010, respectively), consistent with a dilution of risk when either OCD cases with Tourette's syndrome/chronic tics or Tourette's syndrome cases without OCD were incorporated in the discovery sample.
DISCUSSION
Our goal in this study was to leverage phenotypic and genotypic data of two phenotypically related and frequently co-occurring neurodevelopmental disorders, Tourette's syndrome and OCD, to explore the hypothesis that these disorders share common genetic susceptibility variants. Our strategy was 1) to combine the samples in a joint GWAS, 2) to examine their patterns of eQTL/mQTL enrichment, and 3) to explore cross-disorder polygenic signals. Although limited by small sample sizes, the results of these diverse analytic approaches suggest a complex genetic relationship between Tourette's syndrome and OCD.
While our previous work with this sample provides evidence of genetic sharing between Tourette's syndrome and OCD, with a genetic correlation of 0.41 between the two disorders (10), we did not identify any genome-wide significant variants for the combined Tourette's syndrome-OCD phenotype in this GWAS analysis, despite the increase in sample size. However, the combined GWAS signals were significantly enriched for functional alleles (parietal eQTLs), suggesting that these subthreshold variants contain some proportion of Tourette's syndrome-OCD risk loci that are not simply due to stochastic variation. In the presence of genetic heterogeneity (see below), this sample is underpowered to determine whether these loci contribute to susceptibility to both Tourette's syndrome and OCD, or to susceptibility to one or the other individually. As with any genetic association result, replication in an independent sample is required to know whether any of the individual eQTLs identified here are truly shared Tourette's syndrome-OCD susceptibility variants (9, 26, 27).
However, the results of the polygenic analyses do provide strong evidence that OCD and Tourette's syndrome have at least some distinct genetic risk factors. First, the individual disorder analyses confirm that OCD has a significant polygenic component. The proportion of OCD variance explained by directly interrogated SNPs (3.2%) is similar to the findings in schizophrenia (3%-6%) and bipolar disorder (2.8%) (25) , indicating that OCD likely arises from the joint influence of a large number of susceptibility genes spread across the genome, either as common variants or as rare variants in tight linkage disequilibrium with GWAS SNPs. This result is consistent with a parallel heritability study of the same data sets using matching controls) is based on risk scores derived from an aggregated sum of weighted single-nucleotide polymorphism risk allele effect sizes estimated from discovery samples at six significance thresholds. The y axis indicates Nagelkerke's pseudo R 2 . The p value under each discovery sample indicates how well the risk scores derived from the discovery sample can predict the illness phenotype in the target sample. N is the number of cases in each discovery sample. Negative R 2 values indicate a negative correlation between risk scores and illness status in the target sample. OCD EU without known Tourette's/chronic tics=European-ancestry OCD genome-wide association study (GWAS) samples after removing samples with known co-occurring Tourette's/chronic tics; all OCD EU=European-ancestry OCD GWAS samples plus additional EU GWAS samples with co-occurring OCD and Tourette's/chronic tics; combined Tourette's/OCD EU=all European-ancestry Tourette's GWAS samples and OCD GWAS samples; downsized OCD EU=randomly selected subset of OCD EU samples to match the number of cases in the Tourette's EU discovery sample; Tourette's EU=European-ancestry Tourette's GWAS samples; OCD EU trios=the OCD EU parent-child trio probands and matched pseudo-control data derived from nontransmitted alleles; Tourette's FC=Tourette's French Canadian cases and matching controls. A permutation test was carried out to determine the significance of the difference in R 2 between risk scores derived from OCD EU without known Tourette's/chronic tics and all OCD EU, resulting in a two-sided empirical p value of 0.01. The inset box at upper right demonstrates the risk score elevations (difference in risk scores of transmitted alleles and untransmitted alleles in the OCD EU trios, standardized by the risk score of the untransmitted alleles) derived from three discovery samples: OCD EU without known Tourette's/chronic tics, all OCD EU, and combined Tourette's/OCD EU. Two-sided paired t tests were conducted for the pairwise comparisons of risk score elevations derived from three discovery samples.
mixed linear modeling, which found that OCD heritability is concentrated in common variants with minor allele frequencies .30% (10) .
In contrast, the proportion of Tourette's syndrome variance explained was substantially lower (0.6%). Although some of the difference in polygenic risk prediction between OCD and Tourette's syndrome may be due to the smaller discovery sample size for Tourette's syndrome, a sensitivity analysis in which the OCD discovery sample size was reduced to match that of the Tourette's syndrome sample still detected a larger, and statistically significant, OCD polygenic signal than the comparable Tourette's syndrome signal (p=0.01) (see Figure 3 and Table S3 ). The Tourette's syndrome discovery sample was also too small to examine polygenic signals in Tourette's syndrome subgroups (Tourette's syndrome plus OCD versus Tourette's syndrome without OCD); thus, it is possible that the Tourette's syndrome polygenic signal could increase if Tourette's-syndrome-only discovery and target samples were available. The Tourette's syndrome polygenic signal may also have been attenuated by restricting polygenic risk score SNPs to those with minor allele frequencies .5% (done to reduce bias due to undercalling of rare variants; see Supplementary Methods in the data supplement), as this class of SNPs has been shown to account for ∼20% of the variance in liability to Tourette's syndrome, with 80% attributable to common variants (10) . Both the investigation of Tourette's syndrome subgroups and the analysis of polygenic signal including SNPs with minor allele frequencies #5% may be possible in the future as the number of subjects with available GWAS data increases.
The cross-disorder polygenic analyses also provide evidence for genetic heterogeneity between OCD and Tourette's syndrome. First, the polygenic risk scores generated from the individual OCD and Tourette's syndrome discovery samples did not predict case-control status of the other disorder. Second, the combined Tourette's syndrome-OCD sample was a worse predictor of OCD or Tourette's syndrome status than either disorder alone, suggesting that the degree of genetic heterogeneity generated by combining the two phenotypes outweighs any improvement in statistical power due to increased sample size. As noted above, however, our data are likely underpowered to detect a modest shared signal, which we have previously identified in this sample using a mixed-model approach (10).
Although we were not able to examine Tourette's syndrome subgroups, we were able to examine the polygenic composition within OCD subgroups (OCD with or without Tourette's syndrome/chronic tics). These results clearly suggest that OCD with and without chronic tics have different genetic architectures. When OCD cases with cooccurring Tourette's syndrome/chronic tics were added to the OCD discovery sample, the polygenic signal in the independent OCD target sample was attenuated by 35% (permutation p=0.01), despite the 30% increase in sample size. Similarly, the risk score elevation between transmitted and untransmitted alleles dropped substantially with the addition of these 345 OCD cases with co-occurring Tourette's syndrome/ chronic tics (p=0.022).
The hypothesis that OCD may be genetically heterogeneous, with some individuals and families segregating OCD without tics and others a subtype of OCD with tics that may share genetic risk with Tourette's syndrome, was originally proposed by Pauls et al. in 1986 (27) , and more recent epidemiologic studies have provided additional support for this concept (9, 26, 28) .
Although not yet studied, these genetic differences may also correlate with welldocumented differences in treatment outcomes of patients who have OCD alone compared with those who have OCD with tics, in which the latter are more refractory to treatment and may require augmentation with antipsychotics (29) (30) (31) .
Limitations
The primary limitation of this study is related to sample size. While our study represents the largest genetic sample of either disorder studied to date, the total sample of 3,013 case subjects and 5,957 control subjects has 67% power to detect an illness variant with an odds ratio of 1.25 (assuming the risk allele frequency is 20% in the general population), and only 25% power to detect a variant with an odds ratio of 1.20. Recent studies of other psychiatric disorders with evidence of genetic overlap have required substantially larger sample sizes in order to detect individual variants that contribute to both disorders (32, 33) . Therefore, caution is necessary when drawing conclusions about the genetic architecture of Tourette's syndrome and OCD based exclusively on the results of the combined GWAS. However, we have more confidence in our interpretation of the polygenic analyses, which demonstrated significant differences between the aggregate polygenic risk for the Tourette's syndrome-OCD phenotypes despite comparatively small sample sizes. Of note, aggregate polygenic signals have been successfully detected with a comparable number of subjects in other cross-disorder studies as well (32, 33) .
In addition, although we propose that the differences in polygenic risk prediction between Tourette's syndrome and OCD and between OCD with and without tics are due to divergent genetic architectures, alternative explanations should be considered, such as diagnostic misclassification or differences in case ascertainment between study sites or over time. It is also important to note that we focused on common variation, and that rare inherited variation, unique mutations within individual families, de novo mutations, structural variation, and epigenetic and nongenetic factors are all likely contributors to the overall etiology of these related disorders. While our initial studies suggested that common variants account for most of the heritability of Tourette's syndrome and OCD (10) , it is still critically important to explore all of these potential contributors to disease in order to acquire a full understanding of their relative contributions to Tourette's syndrome and OCD.
Finally, interpretation of the eQTL/mQTL analyses is limited by the fact that the tissues analyzed represent a convenience sample based on currently available data, and hence conclusions about tissue specificity should be reserved until larger eQTL data sets across the full range of brain regions and developmental time periods are available. Overall, our results argue that, in addition to some shared genetic variants contributing to susceptibility to either Tourette's syndrome or OCD, genetic variants likely exist that provide phenotypic specificity for each disorder. This observation contrasts with the hypothesis that genes contributing to neuropsychiatric disorders provide a "generalist" framework of neuronal connections from which nongenetic factors determine specific phenotypes, as has been proposed to explain the wide range of phenotypes observed in patients with similar large recurrent copy number variants across various regions of the genome (34, 35) . Furthermore, the apparent difference between OCD with and without tics supports the importance of detailed phenotypic characterization to identify subtype-specific risk alleles in the future. Collection of additional samples through ongoing collaboration will be crucial to further elucidate the specific underlying susceptibility genes for Tourette's syndrome and OCD, both shared and unique.
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